<< CSR 1975-2008 Home

The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 523 KB) and Technical Notes (PDF, 687 KB) pages.



Download and Print: Download Printer-friendly PDF Download data


Table 4.27

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2004-2008
Females by Race
Histologya All Races White Black Asian/
Pacific Islander
American Indian
/Alaska Nativeb
Hispanicc
Count Percent Count Percent Count Percent Count Percent Count Percent Count Percent
Adenocarcinomad 62,981 99.7% 50,790 99.7% 5,690 99.6% 5,523 99.8% 170 100.0% 5,592 99.8%
Adenocarcinoma in situ, NOS (8140/2) - - - - - - - - - - - -
Ductal carcinoma in situe 52,948 83.8% 42,266 83.0% 4,925 86.2% 5,023 90.8% 138 81.2% 4,771 85.1%
Cribiform carcinoma in situ (8201/2) 5,151 8.2% 4,069 8.0% 456 8.0% 534 9.7% 20 11.8% 481 8.6%
Ductal carcinoma in situ, solid type(8230/2) 3,550 5.6% 2,962 5.8% 255 4.5% 300 5.4% - - 297 5.3%
Ductal carcinoma in situ, NOS (8500/2) 21,147 33.5% 17,147 33.7% 1,925 33.7% 1,775 32.1% 58 34.1% 1,817 32.4%
Comedocarcinoma in situ (8501/2) 4,606 7.3% 3,736 7.3% 424 7.4% 388 7.0% - - 431 7.7%
Ductal carcinoma in situ papillary(8503/2) 1,079 1.7% 781 1.5% 154 2.7% 114 2.1% - - 107 1.9%
Noninfiltrating intracystic carcinoma(8504/2) 301 0.5% 208 0.4% 42 0.7% 44 0.8% - - 25 0.4%
Ductal carcinoma in situ micropapillary(8507/2) 1,607 2.5% 1,292 2.5% 179 3.1% 114 2.1% - - 145 2.6%
Intraductal with other types of carcinoma in situ(8523/2) 15,305 24.2% 11,904 23.4% 1,478 25.9% 1,734 31.3% 26 15.3% 1,446 25.8%
Lobular carcinoma in situ (8520/2-8521/2, 8524/2) 7,227 11.4% 6,214 12.2% 506 8.9% 301 5.4% 19 11.2% 582 10.4%
Lobular carcinoma in situ, NOS (8520/2) 7,202 11.4% 6,193 12.2% 503 8.8% 300 5.4% 19 11.2% 582 10.4%
Lobular CISf with other CISf (8524/2) 25 0.0% 21 0.0% - - - - - - - -
Intraductal and lobular in situ carcinoma (8522/2) 2,370 3.8% 1,976 3.9% 212 3.7% 154 2.8% - - 207 3.7%
Other adenocarcinomasg 422 0.7% 321 0.6% 47 0.8% 44 0.8% - - 32 0.6%
Other in situ histologiesh 188 0.3% 150 0.3% 25 0.4% - - - - - -
Total 63,169 100.0% 50,940 100.0% 5,715 100.0% 5,532 100.0% 170 100.0% 5,604 100.0%

Footnotes:

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

d Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

e Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

f CIS = Carcinoma in situ.

g Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

h Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Page Navigation: << Previous Next >>


The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.